Pre-made Ozoralizumab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH), anti-TNFA/TNF;ALB therapeutic antibody, Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ozoralizumab biosimilar, Bispecific Single Domains (VH-VH’-VH), Anti-TNFA/TNF;ALB Antibody: Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
| Products Name (INN Index) | Pre-Made Ozoralizumab biosimilar, Bispecific Single Domains (VH-VH'-VH), Anti-TNFA/TNF;ALB Antibody: Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody |
|---|---|
| INN Name | Ozoralizumab |
| Target | TNFA,ALB |
| Format | Bispecific Single Domains (VH-VH'-VH) |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 5m2j:D;None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Ablynx,Eddingpharm,Pfizer,Taisho Pharmaceutical |
| Conditions Approved | NA |
| Conditions Active | Rheumatoid arthritis |
| Conditions Discontinued | Ankylosing spondylitis,Crohn's disease,Psoriatic arthritis |
| Development Tech | Nanobody Technology |
| Previous Name | NA |
| Gm Offical Target Name | TNFA,ALB |
| Package |
